secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2025-09-17T23:59:59+00:00
Accession:  0001140361-25-035190
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant/Priovant: Phase 3 VALOR brepocitinib meets primary endpoint in dermatomyositis; NDA filing 1H 2026
--------------------------------------------------------------------------------

- Brepocitinib 30 mg achieved week-52 mean TIS 46.5 vs placebo 31.2 (p=0.0006); all 9 key secondary endpoints met.
- 62% of brepocitinib patients on background steroids achieved steroid dose ≤2.5 mg/day vs 34% placebo; 42% off steroids vs 23%.
- Safety profile consistent with prior brepocitinib trials; no increase in AESIs in active arm vs placebo.
- NDA submission for brepocitinib in dermatomyositis planned for calendar first half 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125035190/0001140361-25-035190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125035190/ef20055655_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-035190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer